|
|
| Research article summary (published 29 Jun 2009): |
Patterns of referral of retinal patients for low vision intervention in the anti-VEGF era.
Full Abstract
PURPOSE: The goal of this study was to see how the availability of ranibizumab affected the referral patterns for low vision (LV) evaluation. METHODS: This study used a retrospective review and a comparison of all patients newly referred from retinal Practice 1 (J.T.T., R.N.S.) for LV consultation, from July 2005 to June 2006 (Year 1, preranibizumab) and from July 2006 to June 2007 (Year 2, ranibizumab available), and a retrospective review of patients referred by retinal Practice 2 (M.J.E.) since February 2007. RESULTS: Practice 1: In Year 1, 24 patients with choroidal neovascularization were referred for LV, and in Year 2, only 12 were referred. There was a trend for those patients referred in Year 2 to have worse visual acuity and Pelli-Robson contrast sensitivity than those in Year 1. In Years 1 and 2, 18 and 11 patients with other conditions were referred for LV consultation, respectively. For these patients without choroidal neovascularization, there was no significant difference between groups for visual acuity or contrast sensitivity. Practice 2: The mean best-corrected visual acuity of patients with bilateral choroidal neovascularization referred was 20/145, and no patient had visual acuity > or =20/100. CONCLUSION: Although the use of antivascular endothelial growth factor agents puts visual acuity in a zone more favorable for successful LV intervention, patients with better acuities may not be referred for LV evaluation despite their residual visual impairments and their scotomas, and despite the fact that without LV intervention, they are having difficulty with reading and other activities of daily living. The frequent visits required for monthly injection, the tendency to wait until a course of therapy is complete before referring patients, and a lesser appreciation for the need for LV intervention in patients with only moderate visual loss may be factors in explaining this.
Author information
Author/s: Sunness, Janet S (JS); Schartz, R Brandon (RB); Thompson, John T (JT); Sjaarda, Raymond N (RN); Elman, Michael J (MJ);
Affiliation: Richard E. Hoover Rehabilitation Services for Low Vision and Blindness, Greater Baltimore Medical Center, Baltimore, Maryland 21204, USA. jsunness(-atsign-)gbmc.org
Grants: R03 EY14148 (Agency:NEI NIH HHS)
Journal and publication information
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
Journal: Retina (Philadelphia, Pa.) (Retina), published in United States. (Language: eng)
Reference: -2009 Jul-Aug; vol 29 (issue 7) : pp 1036-9
Dates: Created 2009/07/08; Completed 2009/10/06;
PMID: 19584661, status: MEDLINE (last retrieved date: 10/6/2009)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MeSH Headings (categories) shown below.
Note: Bold headings indicate primary MeSH headings or qualifiers.
Associated Chemicals: Antibodies, Monoclonal (0) ; Vascular Endothelial Growth Factor A (0) ; ranibizumab (0)Related articles
These are the most related articles currently in our database:
- Anti-VEGF therapy: riding the wave of change.
29 Jun 2008 - Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.
3 Oct 2006 - Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab.
29 Apr 2007 - Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.
27 Nov 2006 - A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
7 Sep 2008 - Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
30 Aug 2007 - [Monitoring anti-VEGF drugs for treatment of exudative AMD]
30 Mar 2007 - Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
22 Apr 2007 - Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
30 Apr 2007 - Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
15 Apr 2007
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a larger map of 100+ related articles.